You are here:
LinkedIn-button

Publications

Vaccsheets

Do you want to know more about how Intravacc can help bring your vaccine concept up to proof of concept?

Check our Factsheets, or Vaccsheets as we call them, for more information on our services, products and platforms.

Intravacc - innovating vaccines

Even the most promising vaccines don’t always make it out of the laboratory into large-scale production.

We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines.

How? By bridging the gap between your concept and late stage clinical studies.

GMP facilities

At Intravacc we have two GMP facilities on the campus, Intravacc and BuildingX. We offer pilot GMP production of both viral, bacterial and cancer vaccines. A variety of production technologies are available in both single-use or stainless steel bioreactors.

At Intravacc, the GMP cleanrooms (class c) and quality control span 230 sqm. In BuildingX four labs are available for BSL3 activities (165 sqm). Two of these labs can be used for GMP activities.

Through our partnership network we can produce up to 100 million doses of vaccine.

"*" indicates required fields

3R research: Replacement, Reduction and Refinement of animal experiments

Intravacc is one of the leading organizations in global 3R research (Reduce, Replace and Refine), with a main focus on Reduction, Replacement and Refinement of animal use in statutory required testing for vaccine batch release.

"*" indicates required fields

Intravacc’s proprietary scalable
platform technologies

Intravacc has 4 platforms for vaccine development:

  • Outer Membrane Vesicles (OMV) – Bacterial and Viral
  • Cell-based viral – Vero and HEK 293; vector
  • Conjugation – Infectious diseases; in combination with OMV
  • Adjuvant – LPS and OMV

"*" indicates required fields

Conjugate vaccines

Conjugate vaccines have been extremely successful in preventing disease and death caused by bacterial
infections. Moreover, conjugate vaccines have a superb safety record with very few serious adverse events
following immunization. Intravacc has a 20-year track record in designing, developing and characterizing
conjugate vaccines.

A conjugate vaccine is created by covalently attaching a bacterial polysaccharide, which by itself is not able to induce immunological memory, to a protein carrier antigen, thereby eliciting a stronger immunological response to the antigen.

"*" indicates required fields

Outer Membrane Vesicles (OMV) platform

A novel approach for vaccines is the use of Outer Membrane Vesicles (OMVs). Gram-negative bacteria naturally release OMVs. OMVs are spherical particles (±20-200 nm) that harbour many bacterial antigens which play a role in establishing the infection and survival of the bacterium within the host.

The strongest asset of OMV vaccines is the native conformation of protective antigens. Intravacc has extensive expertise developing OMV vaccines and uses this as a platform technology for various vaccines.

"*" indicates required fields

Vero cell platform technology

The Vero cell line is the most widely used and most reliable cell line in viral vaccine production in terms of quality, yield and safety. At Intravacc, we have been developing viral vaccines using the Vero cell line since 1987.

Intravacc’s cGMP-grade, regulatory approved Vero cell line is currently being used for routine large-scale commercial vaccine manufacturing by clients all over the world.

"*" indicates required fields

Analytical & formulation development

Intravacc is a market leader in vaccine development and complementary analytical services to accelerate your time-to-market.
We offer a wide range of state-of-the-art analytical techniques and vaccine development platforms, bridging the gap between discovery and pilot-scale GMP manufacturing up to Phase I/II clinical trials.

"*" indicates required fields

Virus rescue: tailor-made virus strains

Every viral vaccine project starts with the selection of a virus strain. But finding suitable starting material can be a challenge.
Intravacc can solve these problems for you by designing your viral vaccine candidate and rescuing it, using our reverse genetics system. The result will be a tailor-made infectious progeny virus that you can passage and amplify as required.

"*" indicates required fields

Avacc 2 (R) - First-in-class quadrivalent vaccine against HFMD

Avacc 2® is Intravacc’s next generation quadrivalent vaccine against Hand Foot and Mouth Disease (HFMD), for intramuscular use. Based on our proprietary cell-based platform, it consists of EV71_C4, CVA10, CVA16 and CVA6 inactivated viruses combined with Alum.

"*" indicates required fields

Avacc 7 (R) - Vaccine against Lyme disease

Avacc 7® is Intravacc’s vaccine candidate against Lyme disease, based on our proprietary Outer Membrane Vesicle (OMV) vaccine platform, which is proven to be safe in humans.

"*" indicates required fields

Avacc 10 (R) - Intranasal vaccine against COVID-19

Avacc 10® is Intravacc’s intranasal COVID-19 vaccine candidate, based on our proprietary Outer Membrane Vesicle (OMV) vaccine platform, which is proven to be safe in humans, coupled with spike from SARS CoV-2.

"*" indicates required fields

LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 100+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.